Novo A/S 13D and 13G filings for Inozyme Pharma, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2021-07-30 4:31 pm Sale |
2021-07-26 | 13D | Inozyme Pharma, Inc. INZY |
Novo A/S | 1,167,706 4.970% |
-801,673 (-40.71%) |
Filing |
| 2021-03-30 4:55 pm Sale |
2021-03-25 | 13D | Inozyme Pharma, Inc. INZY |
Novo A/S | 1,969,379 8.400% |
-225,000 (-10.25%) |
Filing |
| 2021-02-01 4:31 pm Sale |
2021-01-28 | 13D | Inozyme Pharma, Inc. INZY |
Novo A/S | 2,194,379 9.400% |
-375,000 (-14.59%) |
Filing |
| 2020-10-05 4:45 pm Unchanged |
2020-09-30 | 13D | Inozyme Pharma, Inc. INZY |
Novo A/S | 2,569,379 11.000% |
0 (Unchanged) |
Filing |
| 2020-07-29 4:42 pm Purchase |
2020-07-28 | 13D | Inozyme Pharma, Inc. INZY |
Novo A/S | 2,569,379 11.500% |
2,569,379 (New Position) |
Filing |